Diasome
1 known investors
Diasome develops the Hepatocyte-Directed Vesicle (HDV) platform to deliver drugs to the liver's portal-hepatic region for improved metabolic control. The company is advancing therapies for diabetes, obesity, and cardiometabolic diseases by targeting hepatocytes rather than peripheral tissues.